Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company's Advanced Cell Diagnostics brand will showcase the technology at booth #222.
During the 'RNAscope: Lightning Lunch and Learn' session on March 25, four leading pathologists will present their research:
- Dr. Rohit Mehra on TRIM63 mRNA as a marker in renal cell carcinoma
- Dr. Vikram Deshpande on albumin mRNA for liver tumors
- Dr. Brooke Howitt on point mutation detection in gynecologic tumors
- Dr. Gregory Bean on mRNA detection from CRTC1/3::MAML2 translocations
The presentations will demonstrate RNAscope's potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.
Positive
- RNAscope technology demonstrates superior performance in biomarker detection compared to traditional methods
- Technology shows potential for improved diagnostic accuracy in multiple cancer types
- Validation of technology by leading pathologists from prestigious institutions
Negative
- Product is currently to research use only, not approved for diagnostic procedures
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was +0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leading pathologists will describe how they have used RNAscope technology to detect clinically relevant biomarkers, including secreted proteins, point mutations and chromosomal translocations, with the potential to improve performance over existing methods and reduce time to results. The session "RNAscope: Lightning Lunch and Learn" at noon on Tuesday, March 25, will highlight four pathologists describing their work using RNAscope technology:
- Dr. Rohit Mehra, Professor of Pathology at the University of
Michigan , will describe TRIM63 mRNA as a surrogate marker in translocation-associated renal cell carcinoma, as an option to traditional DNA FISH. - Dr. Vikram Deshpande, Professor of Pathology at Beth Israel Deaconess Medical Center, will detail how albumin mRNA can be a superior marker to secreted protein in primary and secondary liver tumors.
- Dr. Brooke Howitt, Associate Professor of Pathology at Stanford University, will present advances in the in situ detection of point mutations in molecularly defined gynecologic tumors.
- Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the identification of mucoepidermoid carcinomas and hidradenomas.
"We've made exciting advancements on in situ hybridization methods enabling novel applications in pathology laboratories," commented Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "This conference session highlights the frontier of clinical and translational research by leading pathologists using the latest RNAscope technologies for detecting the molecular underpinnings of disease."
For Research Use Only. Not intended for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-highlight-advances-in-the-detection-of-clinically-relevant-biomarkers-using-rnascope-technologies-at-the-2025-uscap-annual-meeting-302407635.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.